Arvinas, Inc.

ARVN

$9.31

-2.92%

N/A-$0.28

Salud

Biotecnología

NASDAQ

Negociación activa

Arvinas, Inc. es una empresa de biotecnología farmacéutica en la fase de desarrollo clínico, dedicada a identificar, impulsar y comercializar terapias innovadoras ...

Ejecutivos C-Level

(0)

El equipo C-Level forma un liderazgo cohesionado que impulsa la estrategia financiera y la innovación de la empresa.

Miembros clave del equipo

No hay ejecutivos para este nivel

Founder / CEO

C-Level

Board

Director / Board

Other

Key Executives

Name	Title	Compensation	Gender	Year Born	Status
Noah Berkowitz	Director médico	USD 834,887	—	1964	Active
Andrew Saik	Director financiero y tesorero	USD 819,563		1969	Active
Angela Cacace	Director científico	USD 758,163		1968	Active
Randy Teel	CEO, presidente y director	USD 711,098	—	1980	Active
Jared Freedberg	Asesor general y secretario corporativo	—		1969	Active
Alexander A. Santini	Director comercial	—		1959	Active
David Loomis	Vicepresidente y director de contabilidad	—		1974	Active
Jeff Boyle	Vicepresidente de relaciones con inversores	—		—	Active
Paul McInulty	Vicepresidente sénior de asuntos regulatorios	—		—	Active
Steve Weiss	Vicepresidente sénior y director de recursos humanos	—		1970	Active
Kelly Page	Vicepresidente sénior y director global de estrategia y liderazgo de programas de oncología	—		—	Active

Executive Compensation

(deduped by latest filing date per person-year)

Filing Date	Year	Name	Position	Level	Salary	Bonus	Stock Award	Option Award	Incentive	Other	Total
2026-04-29	2025	John Houston, Ph.D.	Former Former President President and Chief Chief Executive Officer	Founder / CEO	$706.24K	$0	$2.69M	$2.67M	$457.00K	$14.00K	$6.53M
2026-04-29	2025	Noah Berkowitz, M.D., Ph.D.	Chief Chief Medical Officer	C-Level	$552.39K	$0	$1.37M	$1.39M	$268.50K	$14.00K	$3.59M
2026-04-29	2025	Andrew Saik	Chief Chief Financial Officer and Treasurer	C-Level	$542.06K	$0	$1.26M	$1.28M	$263.50K	$14.00K	$3.36M
2026-04-29	2025	Angela Cacace, Ph.D.	Chief Chief Scientific Officer	C-Level	$500.76K	$0	$1.26M	$1.28M	$243.40K	$14.00K	$3.30M
2026-04-29	2025	Ian Taylor, Ph.D.	Former Former President President of Research and Development	C-Level	$152.57K	$0	$364.34K	$362.47K	$0	$24.02K	$903.39K
2026-04-29	2024	John Houston, Ph.D.	Former Former President President and Chief Chief Executive Officer	Founder / CEO	$684.00K	$0	$5.85M	$5.77M	$426.82K	$13.80K	$12.75M
2026-04-29	2024	Noah Berkowitz, M.D., Ph.D.	Chief Chief Medical Officer	C-Level	$421.83K	$0	$2.70M	$2.65M	$197.50K	$13.80K	$5.98M
2026-04-29	2024	Ian Taylor, Ph.D.	Former Former President President of Research and Development	C-Level	$367.94K	$0	$1.84M	$1.82M	$172.20K	$13.80K	$4.22M
2026-04-29	2024	Andrew Saik	Chief Chief Financial Officer and Treasurer	C-Level	$272.60K	$0	$1.53M	$1.53M	$127.60K	$4.85K	$3.47M
2026-04-29	2024	Angela Cacace, Ph.D.	Chief Chief Scientific Officer	C-Level	$464.75K	$0	$1.14M	$1.13M	$217.60K	$13.80K	$2.97M
2026-04-29	2023	John Houston, Ph.D.	Former Former President President and Chief Chief Executive Officer	Founder / CEO	$657.70K	$0	$2.13M	$4.35M	$473.60K	$13.20K	$7.63M
2026-04-29	2023	Ian Taylor, Ph.D.	Former Former President President of Research and Development	C-Level	$466.86K	$0	$657.33K	$1.34M	$252.20K	$13.20K	$2.73M

Total Compensation Trend

Sum of disclosed compensation by year (USD million)

Key Roles Compensation Lines

Top founder/C-level executives over time (USD million)

Supply Chain de ARVN

RELATIONS

Upstream

Pfizer Inc. (Pfizer CentreOne / PC1)NYSE:PFEContract Manufacturing Organizations (CMOs) — Multiple Unnamed SuppliersContract Research Organizations (CROs) — Multiple Unnamed SuppliersSpecialty Chemical & Reagent SuppliersActive Pharmaceutical Ingredient (API) Intermediate Suppliers

Downstream

Pfizer Inc.NYSE:PFE Novartis AGNYSE:NVS Rigel Pharmaceuticals, Inc.NASDAQ:RIGL Genentech, Inc. (Roche Group)OTC:RHHBYBayer AGETR:BAYN

Proxies

Kymera Therapeutics, Inc.NASDAQ:KYMR Nurix Therapeutics, Inc.NASDAQ:NRIX C4 Therapeutics, Inc.NASDAQ:CCCC

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal